Literature DB >> 5130433

Effect of rapid intravenous infusion on serum concentrations of amphotericin B.

B T Fields, J H Bates, R S Abernathy.   

Abstract

The magnitude of the concentrations of amphotericin B produced in serum of patients with systemic mycoses may significantly influence the outcome of therapy with this drug. Since amphotericin B is conventionally administered in intravenous infusions lasting 4 to 6 hr, we asked whether faster infusions of this drug might yield higher serum concentrations without an increase in dose. This question was studied in three patients who received 16 infusions of this drug: eight infusions administered slowly (5 hr) and eight administered rapidly (45 min). Serum concentrations after each rapid infusion were compared with those after a slow infusion administered to the same patient. The mean serum concentration of amphotericin B 1 hr after the rapid infusions (2.02 mug/ml) was significantly higher (P < 0.001) than the mean serum concentration of amphotericin B 1 hr after the slow infusions of this drug (1.18 mug/ml). Mean serum concentrations 18 and 42 hr after rapid infusion remained slightly but not significantly higher than respective mean concentrations after slow infusions. By yielding higher initial serum concentration, rapid intravenous infusion may be therapeutically more effective than slow infusion of amphotericin B. Although rapid infusions caused no more toxicity than did slow infusions, the lack of greater toxicity with rapid infusion of amphotericin B should be further documented prior to extensive clinical application of this procedure.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5130433      PMCID: PMC376373          DOI: 10.1128/am.22.4.615-617.1971

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  8 in total

1.  Fungistatic effects of cell free human serum.

Authors:  G L BAUM; D ARTIS
Journal:  Am J Med Sci       Date:  1961-12       Impact factor: 2.378

2.  Experience with amphotericin B for the treatment of systemic mycoses.

Authors:  J H SEABURY; H E DASCOMB
Journal:  AMA Arch Intern Med       Date:  1958-12

3.  Inhibition of growth of pathogenic yeasts by human serum.

Authors:  F J ROTH; M I GOLDSTEIN
Journal:  J Invest Dermatol       Date:  1961-05       Impact factor: 8.551

4.  An automatic method for colorimetric analysis.

Authors:  L T SKEGGS
Journal:  Am J Clin Pathol       Date:  1957-09       Impact factor: 2.493

5.  Coccidioidomycosis and its treatment with amphotericin B.

Authors:  M L LITTMAN; P L HOROWITZ; J G SWADEY
Journal:  Am J Med       Date:  1958-04       Impact factor: 4.965

6.  A pharmacologic guide to the clinical use of amphotericin B.

Authors:  D D Bindschadler; J E Bennett
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

7.  Effect of lipoproteins on hemolytic and antifungal activity of amphotericin B and other polyene antibiotics.

Authors:  G Rebell
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

8.  Amphotericin B serum concentrations during therapy.

Authors:  B T Fields; J H Bates; R S Abernathy
Journal:  Appl Microbiol       Date:  1970-06
  8 in total
  13 in total

1.  Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations.

Authors:  E C Oldfield; P D Garst; C Hostettler; M White; D Samuelson
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Effect of amphotericin B and clotrimazole on lymphocyte stimulation.

Authors:  A Tärnvik; S Ansehn
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

3.  Nephrotoxicity of amphotericin B in dogs: a comparison of two methods of administration.

Authors:  S I Rubin; D R Krawiec; H Gelberg; R D Shanks
Journal:  Can J Vet Res       Date:  1989-01       Impact factor: 1.310

Review 4.  Chemistry and biology of the polyene macrolide antibiotics.

Authors:  J M Hamilton-Miller
Journal:  Bacteriol Rev       Date:  1973-06

5.  Speciation and amphotericin B sensitivity studies on blood isolates of Candida from burned patients.

Authors:  D D Stieritz; E J Law; I A Holder
Journal:  J Clin Pathol       Date:  1973-06       Impact factor: 3.411

6.  Letter: Amphotericin pharmacophobia and renal toxicity.

Authors:  R Forgan-Smith; J H Darrell
Journal:  Br Med J       Date:  1974-02-09

Review 7.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

Review 8.  Chemistry and biology of the polyene macrolide antibiotics.

Authors:  J M Hamilton-Miller
Journal:  Bacteriol Rev       Date:  1973-09

9.  Risk factors of ventricular fibrillation during rapid amphotericin B infusion.

Authors:  P C Craven; D H Gremillion
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

Review 10.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.